These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 36569901)

  • 1. Potent immunomodulatory and antitumor effect of anti-CD20-IL2no-alpha tri-functional immunocytokine for cancer therapy.
    Casadesús AV; Cruz BM; Díaz W; González MÁ; Gómez T; Fernández B; González A; Ledón N; Sosa K; Castro K; López A; Plasencia C; Ramírez Y; Teillaud JL; Hernández C; León K; Hernández T
    Front Immunol; 2022; 13():1021828. PubMed ID: 36569901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highly potent anti-CD20-RLI immunocytokine targeting established human B lymphoma in SCID mouse.
    Vincent M; Teppaz G; Lajoie L; Solé V; Bessard A; Maillasson M; Loisel S; Béchard D; Clémenceau B; Thibault G; Garrigue-Antar L; Jacques Y; Quéméner A
    MAbs; 2014; 6(4):1026-37. PubMed ID: 25072059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A rationally-engineered IL-2 improves the antitumor effect of anti-CD20 therapy.
    Casadesús AV; Deligne C; Diallo BK; Sosa K; Josseaume N; Mesa C; León K; Hernández T; Teillaud JL
    Oncoimmunology; 2020 Jun; 9(1):1770565. PubMed ID: 32923126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An anti-CD20-IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma.
    Gillies SD; Lan Y; Williams S; Carr F; Forman S; Raubitschek A; Lo KM
    Blood; 2005 May; 105(10):3972-8. PubMed ID: 15692062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring complement-dependent cytotoxicity by rituximab isotypes in 2D and 3D-cultured B-cell lymphoma.
    Lara S; Heilig J; Virtanen A; Kleinau S
    BMC Cancer; 2022 Jun; 22(1):678. PubMed ID: 35725455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma.
    Xuan C; Steward KK; Timmerman JM; Morrison SL
    Blood; 2010 Apr; 115(14):2864-71. PubMed ID: 20139095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its antitumor potency.
    Vincent M; Bessard A; Cochonneau D; Teppaz G; Solé V; Maillasson M; Birklé S; Garrigue-Antar L; Quéméner A; Jacques Y
    Int J Cancer; 2013 Aug; 133(3):757-65. PubMed ID: 23354868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-CD20-interferon-β fusion protein therapy of murine B-cell lymphomas.
    Trinh KR; Vasuthasawat A; Steward KK; Yamada RE; Timmerman JM; Morrison SL
    J Immunother; 2013 Jun; 36(5):305-18. PubMed ID: 23719241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Production of an active anti-CD20-hIL-2 immunocytokine in Nicotiana benthamiana.
    Marusic C; Novelli F; Salzano AM; Scaloni A; Benvenuto E; Pioli C; Donini M
    Plant Biotechnol J; 2016 Jan; 14(1):240-51. PubMed ID: 25879373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.
    Klein C; Waldhauer I; Nicolini VG; Freimoser-Grundschober A; Nayak T; Vugts DJ; Dunn C; Bolijn M; Benz J; Stihle M; Lang S; Roemmele M; Hofer T; van Puijenbroek E; Wittig D; Moser S; Ast O; Brünker P; Gorr IH; Neumann S; de Vera Mudry MC; Hinton H; Crameri F; Saro J; Evers S; Gerdes C; Bacac M; van Dongen G; Moessner E; Umaña P
    Oncoimmunology; 2017; 6(3):e1277306. PubMed ID: 28405498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-CD20-interleukin-21 fusokine targets malignant B cells via direct apoptosis and NK-cell-dependent cytotoxicity.
    Bhatt S; Parvin S; Zhang Y; Cho HM; Kunkalla K; Vega F; Timmerman JM; Shin SU; Rosenblatt JD; Lossos IS
    Blood; 2017 Apr; 129(16):2246-2256. PubMed ID: 28137826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complement-Dependent Activity of CD20-Specific IgG Correlates With Bivalent Antigen Binding and C1q Binding Strength.
    Bondza S; Marosan A; Kara S; Lösing J; Peipp M; Nimmerjahn F; Buijs J; Lux A
    Front Immunol; 2020; 11():609941. PubMed ID: 33505398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of rituximab with graphene oxide confers direct cytotoxicity for CD20-positive lymphoma cells.
    Luo C; Deng Z; Li L; Clayton F; Chen AL; Wei R; Miles R; Stephens DM; Glenn M; Wang X; Jensen PE; Chen X
    Oncotarget; 2016 Mar; 7(11):12806-22. PubMed ID: 26859679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas.
    Rosario M; Liu B; Kong L; Collins LI; Schneider SE; Chen X; Han K; Jeng EK; Rhode PR; Leong JW; Schappe T; Jewell BA; Keppel CR; Shah K; Hess B; Romee R; Piwnica-Worms DR; Cashen AF; Bartlett NL; Wong HC; Fehniger TA
    Clin Cancer Res; 2016 Feb; 22(3):596-608. PubMed ID: 26423796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy.
    Lopes JE; Fisher JL; Flick HL; Wang C; Sun L; Ernstoff MS; Alvarez JC; Losey HC
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-glycan engineering of a plant-produced anti-CD20-hIL-2 immunocytokine significantly enhances its effector functions.
    Marusic C; Pioli C; Stelter S; Novelli F; Lonoce C; Morrocchi E; Benvenuto E; Salzano AM; Scaloni A; Donini M
    Biotechnol Bioeng; 2018 Mar; 115(3):565-576. PubMed ID: 29178403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chicken-derived CD20 antibodies with potent B-cell depletion activity.
    Chockalingam K; Kumar A; Song J; Chen Z
    Br J Haematol; 2022 Nov; 199(4):560-571. PubMed ID: 36039695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
    Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
    Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab.
    Rufener GA; Press OW; Olsen P; Lee SY; Jensen MC; Gopal AK; Pender B; Budde LE; Rossow JK; Green DJ; Maloney DG; Riddell SR; Till BG
    Cancer Immunol Res; 2016 Jun; 4(6):509-19. PubMed ID: 27197068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The antitumor effect induced by an IL-2 'no-alpha' mutein depends on changes in the CD8
    Carmenate T; Montalvo G; Lozada SL; Rodriguez Y; Ortiz Y; Díaz C; Avellanet J; Kim J; Surh CD; Graça L; León K
    Front Immunol; 2022; 13():974188. PubMed ID: 36059465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.